[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Missouri-Columbia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":621},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,61,0,25,[9,44,67,101,123,148,166,184,206,233,253,279,299,328,358,377,398,425,443,460,486,508,549,570,596],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100644665","early-phase-1-beta3-adrenergic-receptors-and-cardiovascular-function-in-aging-women-100644665",false,"NCT07674680","Beta3-adrenergic Receptors and Cardiovascular Function in Aging Women","Inclusion Criteria:\n\nHealthy women Assigned female at birth 18-70 years of age Body mass index \\\u003C18 or ≥30 kg\u002Fm2\n\nExclusion Criteria:\n\nAssigned male at birth Pregnancy Breastfeeding History of hormone replacement therapy, chemical menopause, or oophor-ectomy Polycystic ovarian syndrome or Primary ovarian insufficiency Current smoking\u002FNicotine use Blood pressure ≥140\u002F90 mmHg Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy Nerve\u002Fneurologic disease Cardiovascular, hepatic, renal, respiratory disease Hypersensitivity to nitroglycerin Diabetes Communication barriers",true,"FEMALE","18 Years","70 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"EARLY_PHASE1","We hypothesize vascular beta3 adrenergic receptors are present and functional in aging women and can be targeted to attenuate sympathetic vasoconstriction and enhance vascular function in aging women.",[28,29,30],"Women","Aging","Menopause","NOT_YET_RECRUITING","2026-06-23",{"date":34,"type":35},"2026-06-29","ACTUAL",{"date":37,"type":22},"2026-07",{"date":39,"type":22},"2029-05",{"name":41,"class":42},"University of Missouri-Columbia","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":16,"sex":50,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":43},"100641635","early-phase-1-interplay-of-central-and-peripheral-vascular-effects-of-insulin-in-obesity-100641635","NCT07653464","Interplay of Central and Peripheral Vascular Effects of Insulin in Obesity","Inclusion Criteria:\n\n* 18 to 65 years of age\n\nIndividuals with obesity and comorbid IR\n\n* BMI 30-45 kg\u002Fm2\n* Waist circumference ≥102 cm (men) or ≥88 cm (women)\n* HOMA-IR ≥2.5\n\nHealthy normal weight adults\n\n* BMI 18-25 kg\u002Fm2\n* Waist circumference \\\u003C94 cm (men) and \\\u003C80 cm (women)\n* HOMA-IR \\\u003C2\n\nExclusion Criteria:\n\n* Pregnancy, breastfeeding\n* Unable to provide consent\n* Diabetes or polycystic ovarian syndrome\n* Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease, stroke\n* Nerve\u002Fneurologic disease\n* Uncontrolled hypertension (systolic blood pressure \\>180 mmHg and\u002For diastolic blood pressure \\>100 mmHg)\n* Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin)\n* Current smoking, tobacco, nicotine use\n* Use of pharmacological therapy for weight loss\n* Body weight change \\>10% within the last 6 months\n* Adherence to \\>150 min\u002Fweek of moderate-to-vigorous physical activity\u002Fexercise\n* Participation in any other research study or medical procedure involving significant ionizing radiation exposure in the past 12 months\n* Claustrophobia\n* Non-MRI compatible metal implants","ALL","65 Years",{"count":53,"type":22},64,[25],"In the present study, we seek to determine the impact of obesity with insulin resistance on the neurovascular response to brain insulin stimulation.",[57,58],"Obesity (BMI>30)","Insulin Resistance","2026-06-12",{"date":61,"type":35},"2026-06-17",{"date":63,"type":22},"2026-08",{"date":65,"type":22},"2032-06",{"name":41,"class":42},{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":50,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":89,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":43},"100546822","baker-gordon-syndrome-natural-history-study-100546822","NCT06399952","Baker Gordon Syndrome Natural History Study","A Prospective, Longitudinal and Observational Natural History Study for Children and Adults With Baker Gordon Syndrome - Genetic Autism Alliance","BAGOS","Inclusion Criteria:\n\n* Genetically confirmed diagnosis of Baker Gordon syndrome.\n* 0-99 years\n* Ability to send medical records and diagnostic test results.\n* Ability to complete tests and questionnaires.\n\nExclusion Criteria:\n\n• The presence of another condition or co-morbidity unrelated to Baker Gordon syndrome, that affects neurodevelopment.\n\nIn this study, the primary caregivers\u002FLAR for each participant diagnosed Baker Gordon Syndrome will be also considered participants.\n\nCaregivers\u002FLAR will have to meet the following inclusion criteria:\n\n* \\>18 years.\n* Legal caregiver of the patient diagnosed with a Baker Gordon Syndrome.\n* Willingness to follow study procedures, as assessed by the research team.\n* Willingness to sign the consent form.\n* Ability to understand all the information regarding the study, as assessed by the research team.\n\nCaregivers\u002FLAR Exclusion Criteria:\n\n• Less than 18 years old.","0 Years","99 Years",{"count":78,"type":22},50,"OBSERVATIONAL","The goal of this study is to conduct a prospective, longitudinal assessment of the natural clinical progression of children and adults with Synaptotagmin1-Associated Neurodevelopmental Disorder also known as Baker Gordon Syndrome (BAGOS). This will be performed by acquiring baseline measurements and developing effective outcome measures and diagnostic tools for the disorder, to prepare the healthcare system for future clinical trials.",[82,83,84,85,86,87,88],"Rare Diseases","Autism or Autistic Traits","Development Delay","SYT-SSX Fusion Protein Expression","Sleep Disorder","Epilepsy, Generalized","Motor Delay",[90,73,91],"Baker Gordon Syndrome","Synaptotagmin 1-Associated Neurodevelopmental Disorder","RECRUITING","2026-06-01",{"date":95,"type":35},"2026-06-03",{"date":97,"type":35},"2024-04-30",{"date":99,"type":22},"2027-05-05",{"name":41,"class":42},{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":50,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":111,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":43},"100376551","phase-4-subjective-intraoperative-use-of-epidural-steroid-administration-following-discectomy-100376551","NCT04182997","Subjective Intraoperative Use of Epidural Steroid Administration Following Discectomy","Subjective Intraoperative Use of Epidural Steroid Administration Following Discectomy for Herniated Lumbar Discs Is There a Role? - A Randomized Control Trial","Intra-Op","Inclusion Criteria:\n\n* Presenting to the University of Missouri hospital system - including the University of Missouri Hospital and Missouri Orthopaedic Institute - with a clinical assessment indicative of a lumbar disc herniation\n* Failed conservative treatment - rest, anti-inflammatory medications, physical therapy\n* Radiculopathy present - positive tension signs or sensory\u002Fmotor neurologic deficits present\n* Recent MRI confirming single-level lumbar disc herniation corresponding to clinical evaluation\n\nExclusion Criteria:\n\n* Concomitant spinal stenosis, segmental instability, or spondylolisthesis\n* Previous surgery at the affected level or recurrent herniation\n* Underlying disease that may affect response to steroids - immunocompromise, use of chronic steroids or immunosuppression\n* Pregnancy - qualitative human chorionic gonadotropin (hCG) testing will be performed prior to enrollment\n* Diagnosis of or symptoms concerning for cauda equina syndrome",{"count":110,"type":22},200,[112],"PHASE4","The purpose of this study is to determine a grading system for inflammation in lumbar disc herniation and which groups, if any, benefit most from the administration of an intra-operative epidural steroid.",[115],"Lumbar Disc Herniation","2026-05-31",{"date":95,"type":35},{"date":119,"type":35},"2019-11-21",{"date":121,"type":22},"2026-12",{"name":41,"class":42},{"id":124,"slug":125,"hasResults":12,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":12,"sex":50,"minAge":18,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":43},"100639487","growth-hormone-resistance-of-beta-cells-100639487","NCT07581860","Growth Hormone Resistance of Beta-cells","Growth Hormone Resistance of Beta-cells in People With Impaired Fasting Glucose vs Impaired Glucose Tolerance","GHRB-C","Inclusion Criteria:\n\n* body mass index \\>18.5kg\u002Fm2 and \\\u003C45.9kg\u002Fm2\n* impaired fasting glucose \\>\u002F= 100mg\u002FdL, \\\u003C\u002F= 126mg\u002FdL or impaired glucose tolerance on 75g oral glucose tolerance test (blood glucose 140 to 199mg\u002FdL at two-hours)\n\nExclusion Criteria:\n\n* pregnant, planning to become pregnant during the study, or breastfeeding\n* current diagnosis or history of type 1 or type 2 diabetes\n* use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists)\n* history of bariatric surgery\n* known, uncontrolled hypothyroidism\n* history of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment\n* current cancer or cancer that has been in remission less than 5 years\n* first degree relative with type 1 diabetes\n* evidence of anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease)\n* alcohol use disorder, use of controlled substances, or smoking \\>2 cigarettes per day\n* greater than 3% weight loss within three months of screening or engaged in regular (\\>\u002F= 3 days per week), continuous moderate- or high-intensity exercise of \\>\u002F= 30 min duration\n* mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent","59 Years",{"count":133,"type":22},10,"The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with impaired fasting glucose or impaired glucose tolerance at the University of Missouri. The aim of the study is to advance understanding of how growth hormone affects beta-cells and risk factors for developing type 2 diabetes.",[136,137,138,139],"Healthy","Obesity & Overweight","Impaired Fasting Glucose (IFG)","Impaired Glucose Tolerance (Prediabetes)","2026-05-05",{"date":142,"type":35},"2026-05-12",{"date":144,"type":22},"2026-08-01",{"date":146,"type":22},"2030-09-01",{"name":41,"class":42},{"id":149,"slug":150,"hasResults":12,"nctId":151,"briefTitle":152,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":16,"sex":50,"minAge":18,"maxAge":131,"enrollmentInfo":155,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":165,"locationsCount":43},"100560004","growth-hormone-resistance-of-beta-cells-in-people-with-a-family-history-of-type-2-diabetes-100560004","NCT06571500","Growth Hormone Resistance of Beta-cells in People With a Family History of Type 2 Diabetes","GHRB-B","Inclusion Criteria:\n\n* 18 to 59 years old\n* body mass index ≥30.0 kg\u002Fm2 and \\\u003C45.0 kg\u002Fm2\n\nAdditional, group-specific inclusion criteria:\n\n* Family history of type 2 diabetes: first degree relative with type 2 diabetes\n* Control group: no family history of type 2 diabetes\n\nExclusion Criteria:\n\n* Pregnant, planning to become pregnant during the study, or breastfeeding\n* Current diagnosis or history of type 1 or type 2 diabetes\n* Use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists)\n* History of bariatric surgery\n* Known, uncontrolled hypothyroidism\n* History of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment\n* Current cancer or cancer that has been in remission less than 5 years\n* First degree relative with type 1 diabetes diagnosis\n* Evidence of significant anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease)\n* Alcohol use disorder, use of controlled substances, or smoking \\>2 cigarettes per day\n* Greater than 3% weight loss within three months of screening or engaged in regular (≥3 days per week), continuous moderate- or high-intensity exercise of ≥30 min duration\n* Mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent",{"count":156,"type":22},30,"The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with a family history of type 2 diabetes at the University of Missouri. Our aim is to advance understanding of how growth hormone affects beta-cells and risk factors for developing type 2 diabetes.",[136,159],"Obesity",{"date":161,"type":35},"2026-05-11",{"date":163,"type":35},"2025-07-15",{"date":146,"type":22},{"name":41,"class":42},{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":179,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":183,"locationsCount":43},"100560003","growth-hormone-resistance-of-beta-cells-a-100560003","NCT06571487","Growth Hormone Resistance of Beta-cells A","Growth Hormone Resistance of Beta-cells in Women With Gestational Diabetes Mellitus","GHRB-A","Inclusion Criteria:\n\n* Singleton, full term pregnancy within the past 5 years\n* Body mass index ≥18.5 kg\u002Fm2 and \\\u003C45.0 kg\u002Fm2\n\nGroup specific inclusion criteria:\n\n* Gestational Diabetes Group: History of gestational diabetes in the most recent pregnancy\n* Control Group: no history of gestational diabetes\n\nExclusion Criteria:\n\n* Pregnant, planning to become pregnant during the study, or breastfeeding\n* Current diagnosis or history of type 1 or type 2 diabetes\n* Use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists)\n* History of bariatric surgery\n* Known, uncontrolled hypothyroidism\n* History of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment\n* Current cancer or cancer that has been in remission less than 5 years\n* First degree relative with diabetes diagnosis\n* Evidence of significant anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease)\n* Alcohol use disorder, use of controlled substances, or smoking \\>2 cigarettes per day\n* Greater than 3% weight loss within three months of screening or engaged in regular (≥3 days per week), continuous moderate- or high-intensity exercise of ≥30 min duration\n* Mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent","45 Years",{"count":156,"type":22},"The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with a personal history of gestational diabetes (high blood sugar in pregnancy) at the University of Missouri. The aim of the study is to advance understanding of how growth hormone affects beta-cells and risk factors for developing gestational diabetes.",[178,159,136],"Gestational Diabetes",{"date":161,"type":35},{"date":181,"type":35},"2025-10-22",{"date":146,"type":22},{"name":41,"class":42},{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":16,"sex":50,"minAge":174,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":23,"phases":195,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":200,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":43},"100457351","high-protein-diet-and-atherosclerosis-100457351","NCT05235464","High Protein Diet and Atherosclerosis","Dissecting the Impact of Dietary Protein on Macrophage mTOR Signaling and Atherosclerosis","HPA","Inclusion Criteria:\n\n* \\>=45 and \\\u003C=75 years of age\n* body mass index \\>=25.0 and \\\u003C40.0 kg\u002Fm2\n\nExclusion Criteria:\n\n* \\\u003C45 and \\>75 years of age\n* body mass index \\\u003C25.0 or \\>39.9 kg\u002Fm2\n* plasma triglyceride \\\u003C125 mg\u002Fdl\n* history of or current significant organ system dysfunction\n* allergies or intolerances to meal ingredients\n* use of medications or dietary supplements that could confound the study outcomes\n* engaged in regular structured exercise \\>150 min per week\n* alcohol use disorder\n* premenopausal women\n* persons who smoke\n* prisoners\n* inability to grant voluntary informed consent","75 Years",{"count":194,"type":22},24,[196],"NA","Atherosclerosis is the underlying cause of the majority of cardiovascular diseases, including myocardial infarction and strokes, and results in tremendous morbidity and mortality. A Western-type diet is a major risk factor for atherosclerosis because of the high saturated fat, cholesterol, and refined carbohydrate contents. Dietary strategies to reduce cardiovascular disease burden therefore focus on restriction of saturated fat, cholesterol, and refined carbohydrates whereas \"lean\" protein intake is recommended and has become popular. However, results from studies conducted in animal models suggest high dietary protein intake is also atherogenic. The investigators' extensive preliminary data in animal models show that dietary protein increases atherosclerotic plaque formation and size and promotes necrotic core formation, a characteristic of rupture-prone plaques. The goal of the current proposal is to provide deeper insights into the relationship between protein intake and the pathogenesis of atherosclerosis by studying the mechanisms involved in protein-mediated atherogenesis and formation of necrotic plaques. The overarching hypothesis is that high protein intake drives atherosclerosis via leucine-mediated mTORC1 signaling in macrophages, which inhibits macrophage mitophagy and aggrephagy and stimulates macrophage proliferation. Furthermore, the investigators hypothesize that proteins from animal sources are more atherogenic than proteins from plant sources, because animal proteins contain more leucine than plant proteins. The investigators will test these hypotheses by using a sophisticated array of experimental strategies, including assays in primary macrophages and human monocyte-derived macrophages and genetically engineered mouse models. In addition, they will begin to translate the results obtained in vitro and in animals to people, and explore approaches to pharmacologically target the pro-atherogenic pathways as novel cardiovascular therapeutics. This proposal represents a paradigm shift in how a Western-type diet affects vascular health which has important implications since many adults in Western societies consume excess protein and dietary protein is heavily marketed for its presumed beneficial health effects.",[199],"Atherosclerosis",{"date":161,"type":35},{"date":202,"type":35},"2023-03-13",{"date":204,"type":22},"2028-03-31",{"name":41,"class":42},{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":16,"sex":50,"minAge":213,"maxAge":19,"enrollmentInfo":214,"targetDuration":4,"studyType":23,"phases":216,"briefSummary":217,"conditions":218,"keywords":222,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":43},"100362068","animal-and-plant-proteins-and-glucose-metabolism-100362068","NCT03994367","Animal and Plant Proteins and Glucose Metabolism","HP","Inclusion Criteria:\n\n* age: ≥21 and ≤70 years;\n* BMI: \\>24.5 and \\\u003C32.5 kg\u002Fm2;\n* habitual protein intake \\\u003C0.9 g\u002Fkg\u002Fday (assessed on 2 weekdays and 2 weekend days by using the HealthWatch 360 app); and\n* weight stable (i.e., ≤3% change) and untrained (≤150 min of structured exercise\u002Fweek) for at least 2 months before entering the study.\n\nExclusion Criteria:\n\n* prediabetes or type 2 diabetes;\n* evidence of chronic kidney disease by medical history or laboratory tests (glomerular filtration rate \\\u003C60 ml\u002Fmin\u002F1.73 m2 or an albumin to creatinine ratio in urine ≥30 mg\u002Fg);\n* vegetarians or vegans;\n* intolerance or allergies to ingredients in the metabolic meal or intervention diet;\n* take dietary supplements (e.g., pre- and probiotics, fiber, fish oil) or medications known to affect our study outcomes;\n* received antibiotic or antifungal treatment (which affect the microbiome and therefore microbial metabolite production) 2 months before entering the study;\n* consume tobacco products or excessive alcohol (women: \\>14 drinks\u002Fweek; men: \\>21 drinks\u002Fweek);\n* evidence of significant organ system dysfunction or diseases (e.g., cirrhosis), and\n* unwilling or unable to provide informed consent.","21 Years",{"count":215,"type":22},100,[196],"The goal of this proposal is to determine the effect of a high protein diet in which the increase in protein intake is derived from different sources (animal vs plant and protein-rich whole foods vs protein isolates) on: i) liver and muscle insulin sensitivity; ii) the metabolic response to a meal, and iii) 24-h plasma concentration profiles of glucose, glucoregulatory hormones, and protein-derived metabolites purported to cause metabolic dysfunction.",[219,220,221],"Metabolic Syndrome","Metabolic Syndrome, Protection Against","Glucose Metabolism Disorders",[223,224,225],"High Protein","Metabolism","Diet",{"date":227,"type":35},"2026-05-08",{"date":229,"type":35},"2019-07-12",{"date":231,"type":22},"2028-04-25",{"name":41,"class":42},{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":50,"minAge":18,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":23,"phases":241,"briefSummary":242,"conditions":243,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":43},"100635479","talar-osteochondral-lesions-with-pilon-fractures-100635479","NCT07553221","Talar Osteochondral Lesions With Pilon Fractures","Incidence and Management Implications of Talus Osteochondral Lesions in Tibial Plafond (Pilon) Fractures Identified Via Nano-Arthroscopy at Time of External Fixation: A Pilot Study","Inclusion Criteria:\n\n* Age ≥ 18 years (skeletally mature) Tibial plafond fractures with impaction of the articular surface requiring external fixation for temporization AO\u002FOrthopaedic Trauma Association (OTA) Fracture classification 43-C type fractures (excluding posterior pilon or supination-adduction type ankle fractures) Closed injury\n\nExclusion Criteria:\n\n* Prior ankle surgery\n\n  * Pre-existing ankle arthritis\n  * Unstable polytrauma patients precluding safe temporization\n  * Concomitant talus or calcaneus fractures identifiable on plain radiographs\n  * Pregnant\n  * Prisoner\n  * Unable to Consent",{"count":7,"type":22},[196],"Patients with pilon fractures have a high incidence of talar osteochondral lesions. In this study, patients will undergo ankle arthroscopy at the time of external fixation. The objective is to help determine the incidence of these lesions with pilon fractures and to see if these nano-arthroscopy results change the plan for definitive treatment.",[244],"Pilon Fractures","2026-04-30",{"date":247,"type":35},"2026-05-06",{"date":249,"type":22},"2026-04",{"date":251,"type":22},"2031-04",{"name":41,"class":42},{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":12,"sex":50,"minAge":18,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":23,"phases":263,"briefSummary":264,"conditions":265,"keywords":267,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":278},"100594742","effectiveness-of-and-implementation-strategies-for-disfrutando-100594742","NCT07023406","Effectiveness of and Implementation Strategies for 'Disfrutando'.","Effectiveness of and Implementation Strategies for 'Disfrutando': A Culturally Tailored, Bundled Intervention to Address Type 2 Diabetes Mellitus in High-burden Populations","Disfrutando 2","Inclusion Criteria:\n\n* Hemoglobin A1C of 5.7 or higher\n\nExclusion Criteria:\n\n* Hemoglobin A1C of 5.6 or lower",{"count":262,"type":22},31,[196],"Despite much research that has focused on enhancing type 2 diabetes mellitus (T2DM) health outcomes for high burden populations, more remains to be done. There is a need to develop practical approaches that not only equip people with knowledge about T2DM self-management, but also help them mitigate the adverse social determinants of health (SDOH) that are fueling the burgeoning numbers of people in the United States with T2DM and that are preventing them from practicing healthful behaviors. This study will examine an intervention named 'Disfrutando' that strives to help people prevent and manage T2DM.",[266],"Type 2 Diabetes Mellitus (T2DM)",[268,269,270],"Participatory Research","T2DM","High-Burden Populations",{"date":272,"type":35},"2026-05-07",{"date":274,"type":35},"2025-08-01",{"date":276,"type":22},"2026-07-31",{"name":41,"class":42},2,{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":285,"enrollmentInfo":286,"targetDuration":4,"studyType":23,"phases":287,"briefSummary":288,"conditions":289,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":43},"100504294","effect-of-drain-care-on-infection-rate-and-quality-of-life-in-implant-based-breast-reconstruction-100504294","NCT05846438","Effect of Drain Care on Infection Rate and Quality of Life in Implant-Based Breast Reconstruction.","Inclusion Criteria:\n\n* undergoing breast surgery with placement of tissue expander and drains, acceptance of protocol and procedures, age \\> 18\n\nExclusion Criteria:\n\n* no existing wounds, previous infections related to implant device if delayed, refusal by patient","100 Years",{"count":215,"type":22},[196],"The goal of this clinical trial is to learn whether showering with surgical drain tubes in place after first stage breast reconstruction causes increased risk of infection. The main questions it aims to answer are:\n\n* Is there an increased risk of infection\u002Fcomplications with showering 48 hours after drain tubes are in place\n* Does showering after 48 hours with drain tubes in place affect quality of life.",[290,291],"Infections","Quality of Life","2026-04-28",{"date":140,"type":35},{"date":295,"type":35},"2023-03-15",{"date":297,"type":22},"2028-03-15",{"name":41,"class":42},{"id":300,"slug":301,"hasResults":12,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":12,"sex":50,"minAge":306,"maxAge":307,"enrollmentInfo":308,"targetDuration":4,"studyType":23,"phases":309,"briefSummary":310,"conditions":311,"keywords":313,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":43},"100625549","metacognitive-strategy-training-intervention-for-transition-age-youth-with-cerebral-palsy-100625549","NCT07424079","Metacognitive Strategy Training Intervention for Transition-Age Youth With Cerebral Palsy","The Feasibility of Remote Pathways and Resources for Engagement and Participation (PREP) for Transition-Age Youth With Cerebral Palsy and Primary Caregivers","Inclusion Criteria:\n\n* Youth aged 13 -17 with CP and one primary parent, guardian, or caregiver aged 18 or older\n* Youth ability to self-mobilize with or without adaptive equipment measured by the Gross Motor Function Scale-Expanded \\& Revised (GMFCS-E\\&R) Levels I - III\n* Effective youth communication measured by Communication Function Classification System (CFCS) Levels I - III\n* Ability to read, speak, and write English\n* Willingness to participate in all aspects of the proposed study.\n\nExclusion Criteria:\n\n* Youth with profound intellectual disability\n* Youth with severe mental health conditions\n* Youth who engage in community-based transition services redundant with remote PREP","13 Years","17 Years",{"count":194,"type":22},[196],"This exploratory randomized controlled trial will examine the feasibility and preliminary effects of a remote PREP intervention compared to an attention control for transition-age youth with cerebral palsy and their caregivers. Youth-caregiver dyads will complete remote baseline assessments and be randomized to a 12-week intervention or attention control, with weekly virtual sessions. Feasibility outcomes will be primary, with secondary outcomes exploring preliminary efficacy. Post-intervention assessments and optional interviews will be conducted remotely to capture outcomes and participant experiences.",[312],"Cerebral Palsy (CP)",[314,315,316,317,318,319],"Cerebral Palsy","Occupational Therapy","Adolescents","Caregivers","Transition Planning","Participation","2026-04-27",{"date":322,"type":35},"2026-05-01",{"date":324,"type":22},"2026-05-15",{"date":326,"type":22},"2027-02-28",{"name":41,"class":42},{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":12,"sex":50,"minAge":18,"maxAge":335,"enrollmentInfo":336,"targetDuration":4,"studyType":23,"phases":338,"briefSummary":339,"conditions":340,"keywords":345,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":352,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":43},"100622552","evaluation-of-cognitive-behavioral-therapy-for-insomnia-cbt-i-in-individuals-with-mild-traumatic-brain-injury-mtbi-100622552","NCT07385105","Evaluation of Cognitive Behavioral Therapy for Insomnia (CBT-I) in Individuals With Mild Traumatic Brain Injury (mTBI)","Exploring Cognitive Behavioral Therapy for Insomnia (CBT-I) in Mild Traumatic Brain Injury (mTBI)","Inclusion Criteria:\n\n* A history of mTBI documented by a physician and sleep problems for more than 4 weeks\n* A score ≥ 10 on the Insomnia Severity Index (ISI)\n* Speak, read, and write English\n\nExclusion Criteria:\n\n* History of other neurological or psychological conditions\n* Patient Health Questionnaire-9 (PHQ-9) score higher than 20 (severe depressive symptoms)\n* Generalized Anxiety Disorder-7 (GAD-7) score higher than 15 (severe anxiety symptoms)\n* Montreal Cognitive Assessment (MoCA) score less than 24","60 Years",{"count":337,"type":22},15,[196],"This study will employ cognitive behavioral therapy for insomnia (CBT-I) among individuals with mild traumatic brain injury (mTBI) who experience sleep disturbances. The research aims to evaluate the effects of CBT-I on sleep, mTBI symptoms, and, in particular, the ability of individuals with mTBI to engage in their desired daily life activities. The main questions this study aims to answer are:\n\n1. Does CBT-I positively impact symptoms of mTBI?\n2. Does CBT-I improve functional performance in individuals with mTBI?",[341,342,343,344],"Sleep Architecture","Mild Traumatic Brain Injury","Sleep","Sleep and Circadian Problems",[346,347,348,349,350,351],"Sleep problems","Cognitive behavioral Therapy for insomnia","CBT-I","mild traumatic brain injury","mTBI","Functional performance",{"date":322,"type":35},{"date":354,"type":35},"2026-03-01",{"date":356,"type":22},"2027-01-01",{"name":41,"class":42},{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":16,"sex":50,"minAge":18,"maxAge":365,"enrollmentInfo":366,"targetDuration":4,"studyType":23,"phases":368,"briefSummary":369,"conditions":370,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":372,"startDateStruct":373,"completionDateStruct":374,"leadSponsor":376,"locationsCount":4},"100618589","insomnia-and-insulin-resistance-100618589","NCT07333586","Insomnia and Insulin Resistance","Insomnia, Metabolic Syndrome and Insulin Resistance","Inclusion Criteria:\n\nages 18-50 y BMI 28-45 kg\u002Fm2 Score on the Insomnia Severity Index ≥15.\n\nExclusion Criteria:\n\ncontraindications for CBT-I (mania or seizure disorder) symptoms requiring immediate attention (e.g., psychosis, suicide intent) report illicit substance use on a monthly basis (e.g., cocaine, opioids) receiving behavioral treatment for insomnia overt cardiovascular disease overt renal disease thyroid disease cancer pregnant dieting using GLP-1 agonists taking exogenous insulin","50 Years",{"count":367,"type":22},20,[196],"Insomnia symptoms are linked to metabolic syndrome (MetS), which includes abnormal glucose metabolism, insulin resistance (IR), and incidence of diabetes. Chronic sleep deficit is a major predictor of disease and early mortality. Further, insomnia is the most common sleep disorder in the United States. The recommended first line of treatment for insomnia is Cognitive Behavioral Therapy for Insomnia (CBT-I). CBT-I is a multidimensional treatment that targets the thoughts and behaviors that perpetuate insomnia symptoms over time. This study will explore CBT-I effects on MetS outcomes (ie. blood pressure, triglycerides, etc.) and provide preliminary evidence that CBT-I impacts IR and fasting glucose concentrations within this population.\n\n20 subjects with insomnia will be recruited. They will be randomly assigned to either CBT-i or sleep hygiene. The intervention is 5 wks. Pre and post intervention, the investigator will have participants fill out a number of questionnaires, a daily sleep diary, 2 weeks of actigraphy measuring sleep and physical activity and there will be a single blood draw at the beginning and the end of the study.",[371,58],"Insomnia",{"date":292,"type":35},{"date":93,"type":22},{"date":375,"type":22},"2027-06-01",{"name":41,"class":42},{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":4,"eligibilityCriteria":383,"healthyVolunteers":12,"sex":50,"minAge":306,"maxAge":213,"enrollmentInfo":384,"targetDuration":4,"studyType":23,"phases":385,"briefSummary":386,"conditions":387,"keywords":389,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":392,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":43},"100609562","the-feasibility-of-a-remote-problem-solving-intervention-for-autistic-adolescents-or-young-adults-and-a-caregiver-100609562","NCT07216196","The Feasibility of a Remote Problem-Solving Intervention for Autistic Adolescents or Young Adults and a Caregiver","The Effect of Dyadic Metacognitive Strategy Training in Autistic Youth or Young Adults and a Primary Caregiver","Inclusion Criteria:\n\n* Autistic adolescents aged 13-21 AND one primary parent, guardian, or caregiver aged 18 or older\n* At least one year remaining in high school\n* Ability to engage in reciprocal conversation\n* Ability to provide informed consent\u002Fassent as part of an adapted procedure designed to prevent coercion and protect the rights of autistic adolescents with or without intellectual disability\n\nExclusion Criteria:\n\n* Severe or profound intellectual disability (IQ\\\u003C35)\n* Severe mental health conditions that interfere with ability to participate in the intervention\n* Currently enrolled in community-based transition services redundant with remote PREP",{"count":194,"type":22},[196],"This project seeks to evaluate the feasibility and acceptability of a remote metacognitive strategy training intervention in transition-age autistic adolescents and young adults and a primary caregiver. We will also conduct limited efficacy testing.",[388],"Autism",[315,388,390,391],"Transition to Adulthood","Waitlist Crossover",{"date":292,"type":35},{"date":394,"type":35},"2026-04-08",{"date":396,"type":22},"2027-05-03",{"name":41,"class":42},{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":16,"sex":50,"minAge":18,"maxAge":4,"enrollmentInfo":404,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":406,"conditions":407,"keywords":414,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":419,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":43},"100273409","tumor-cell-and-dna-detection-in-the-blood-urine-and-bone-marrow-of-patients-with-solid-cancers-100273409","NCT02838836","Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers","Inclusion Criteria:\n\n* Subjects older than 18 years.\n* Subjects of all genders and ethnicities.\n* Subjects with the diagnosis of a solid cancer (n=100) of all stages will be included (lung, esophageal, stomach, bile duct\u002Fpancreas, colorectal, melanoma, sarcoma).\n* Ten patients with no present suspicion and no previous history of any cancer (except basal cell cancer of the skin) that undergo surgeries for other benign indications will serve as controls (n=20).\n* In patients undergoing surgery for cancer the histopathology should preferably be pathologically proven by a previous or novel biopsy. Yet, patients with a high cancer suspicion by radiology and clinical picture that undergo cancer surgery will not be excluded. No additional biopsies, testing or interventions will be performed for the purpose of this study if the medical treatment will not require it.\n* Subjects must be capable of giving informed consent.\n\nExclusion Criteria:\n\n* Pregnant women.\n* Subjects with the concurrent diagnosis of an active secondary (synchronous) malignancy besides basal cell carcinoma of the skin will be excluded, if there is evidence of disease burden or if the patient is currently being treated with chemotherapy.\n* Subjects with a hemoglobin of \\\u003C8g\u002Fdl in the morning of the procedure will be excluded.\n* In subjects who require intraoperative transfusions of \\>4 units of red packed blood cells (RPBCs), no further blood will be drawn for CTC\u002FDTC\u002FcfDNA analysis during surgery or on postoperative day 1.\n* In patients with coagulation disorders that could lead to significant bleeding (such as hemophilia, significant thrombocytopenia) requiring prophylactic administration of coagulative products, no bone marrow aspiration will be performed.",{"count":405,"type":22},620,"Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery. Circulating and disseminated tumor cell (CTC\u002FDTC) and circulating cell-free (cf) DNA isolation from the blood, urine and bone marrow will increase understanding of cancer spread and advance knowledge to develop individualized therapies.",[408,409,410,411,412,413],"Non-small Cell Lung Cancer","Esophageal Cancer","Gastric Cancer","Pancreatic Cancer","Hepatocellular Cancer","Colorectal Cancer",[415,416,417,418],"Cancer","Circulating tumor cells (CTCs)","Disseminated tumor cells (DTCs)","Circulating tumor DNA (ctDNA)",{"date":322,"type":35},{"date":421,"type":35},"2016-07-01",{"date":423,"type":22},"2027-12-01",{"name":41,"class":42},{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":429,"acronym":4,"eligibilityCriteria":430,"healthyVolunteers":12,"sex":50,"minAge":18,"maxAge":4,"enrollmentInfo":431,"targetDuration":4,"studyType":23,"phases":432,"briefSummary":433,"conditions":434,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":442,"locationsCount":43},"100470089","phase-4-skin-preparation-for-elective-foot-and-ankle-surgery-100470089","NCT05401292","Skin Preparation for Elective Foot and Ankle Surgery","Inclusion Criteria:\n\n* patients undergoing elective foot and ankle surgeries\n* age over 18\n\nExclusion Criteria:\n\n* trauma as the indication for surgery\n* open injuries\n* non-elective procedures\n* amputations\n* prior surgical site infection through the planned incision\n* pregnancy. All potential participants of child-bearing potential follow the standard pre-operative protocol to ensure they are not in pregnant status prior to SOC surgical procedure.",{"count":215,"type":22},[112],"Surgical site infections (SSIs) make about 31% of all nosocomial infections and they are the most common hospital-acquired infection. For foot and ankle elective interventions, SSI rate is reported between 0.4% and 3.6%. This study will investigate the effectiveness of skin cleaning with isopropyl alcohol and scrubbing with chlorhexidine soap before standard skin preparation in reducing microbial load and surgical site infections for elective foot and ankle surgeries. Current standard of care includes skin preparation with iodine or chlorhexidine solution prior to sterile draping and the start of surgery. Standard of care will be applied to all patients. The use of an additional \"pre-scrub\" with isopropyl alcohol and scrubbing with chlorhexidine soap will be applied to the experimental group. The control group will receive only the standard of care skin preparation with iodine or chlorhexidine solution prior to draping.",[435,436],"Microbial Colonization","Foot and Ankle Disorders","2026-04-23",{"date":320,"type":35},{"date":440,"type":35},"2022-02-15",{"date":121,"type":22},{"name":41,"class":42},{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":50,"minAge":18,"maxAge":4,"enrollmentInfo":450,"targetDuration":4,"studyType":23,"phases":451,"briefSummary":452,"conditions":453,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":455,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":459,"locationsCount":43},"100335848","phase-4-pilon-fracture-with-intra-articular-injection-of-n-acetylcysteine-pilon-nac-100335848","NCT03652753","Pilon Fracture With Intra-articular Injection of N-Acetylcysteine (Pilon NAC)","Prevention of Cartilage Cell Death Following a Pilon Fracture With Intra-articular Injection of N-Acetylcysteine (Pilon NAC)","Inclusion Criteria:\n\n* Closed high energy pilon fracture requiring a staged procedure\n\nExclusion Criteria:\n\n* Younger than 18\n* Open fracture\n* Intra-articular injury not requiring a staged procedure\n* Allergy to NAC\n* Wounds preventing safe intra-articular injection\n* Unwilling to participate in the study\n* Pregnancy",{"count":156,"type":22},[112],"High energy intra-articular fractures of the distal tibia, or Pilon fracture, is a devastating injury with multiple short and long term complications. The incidence of these injuries is increasing as survival rates after motor vehicle collisions increase. The current standard of care for high energy pilon fractures is to place an external fixator at the time of injury and then provide definitive internal fixation when the soft tissue envelope allows, which is usually around 10-14 days. Arguably, the most debilitating long term complication after a high energy pilon fracture is the development of post-traumatic osteoarthritis (PTOA), which occurs in 50% or more of pilon fractures within the first 2 years of surgery. The development of osteoarthritis occurs even in the presence of adequate restoration of the tibial plafond. Part of this issue lies in the fact that ankle joint cartilage is the thinnest of any major articular joint and sustains a great deal of damage at the time of injury. This impaction and injury initiates a cascade of events that ultimately result in cartilage cell death, or chondrolysis. Chondrolysis occurs via necrosis or apoptosis. Apoptosis occurs via a caspase pathway, while necrosis of chondrocytes likely occurs secondary to overproduction of reactive oxidant species (ROS). Recent animal models have demonstrated several things: chondrocyte death is highest along fracture lines, and likely undergo necrosis as opposed to apoptosis. The reason that PTOA likely occurs in such a high percentage of pilon fractures is because of this chondrolysis, and if a method can be developed to decrease the rate of chrondrocyte necrosis, then the rate of PTOA could potentially improve and improve patient outcomes overall. A recent bovine model examined the injection of N-acetylcysteine (NAC) after an intra-articular knee fracture and its effect on the cartilage cell viability. Their study demonstrated that chondrocyte cell viability after an injection of NAC within four hours of injury decreased chondrolysis from roughly 60% to about 30% at 48hrs. The effect was greater the closer to injury the injection occurred, and was statistically significant for 2 weeks. This indicates that free radical scavengers can potentially improve cartilage cell viability and help prevent the development of PTOA. No studies have been published on humans regarding injection of NAC after a fracture. However, a recent article examined the injection of NAC into osteoarthritic knees and found that it was effective in lowering certain cartilage degradation markers and was comparable to hyaluronic acid for both pain and function. NAC has been proven safe for both intra-articular injections and systemic injections in humans. Our study will focus on the improvement of cartilage cell viability with an injection of NAC. Our hypothesis is that the NAC intra-articular injection will increase the percentage of viable cartilage cell after sustaining a pilon fracture, when compared to a placebo injection of saline.\n\nThe goal of this study is to examine the effects of an intra-articular injection of the amino acid NAC on cartilage cells after an intra-articular fracture of the ankle joint. The long-term clinical goal of this research is to reduce the incidence of post-traumatic osteoarthritis in the ankle joint after fracture.",[454],"Pilon Fracture",{"date":292,"type":35},{"date":457,"type":35},"2019-01-01",{"date":121,"type":22},{"name":41,"class":42},{"id":461,"slug":462,"hasResults":12,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":466,"eligibilityCriteria":467,"healthyVolunteers":12,"sex":50,"minAge":174,"maxAge":468,"enrollmentInfo":469,"targetDuration":4,"studyType":23,"phases":470,"briefSummary":471,"conditions":472,"keywords":474,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":480,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":43},"100561321","improving-participation-after-stroke-self-management-rehabilitation-100561321","NCT06588647","Improving Participation After Stroke Self-Management-Rehabilitation","Efficacy of the Improving Participation After Stroke Self-Management-Rehabilitation (IPASS-R) Program in Sub-acute Stroke","IPASS-R","Inclusion Criteria:\n\n* less than 6 months post-stroke\n* age 45-85 years\n* completed inpatient rehabilitation services (if recommended)\n* living in the community with or without caregiver support (i.e., not living in a skilled nursing facility)\n* ability to read, write, and speak English\n* diagnosis of mild or moderate stroke (National Institutes of Health stroke score \\\u003C16)\n* able to use videoconferencing independently or with caregiver support\n\nExclusion Criteria:\n\n* severe depressive symptoms as indicated by a score ≥21 on the Patient Health Questionnaire\n* dementia symptoms as indicated by a score of \\\u003C23 on the Montreal Cognitive Assessment\n* additional neurological diagnoses (e.g., brain malignancy, previous severe stroke)\n* (4) moderate or severe aphasia as indicated by a National Institutes of Health Stroke Scale aphasia score of ≥ 2\n* inability to provide informed consent\n* any other condition not otherwise specified that the PI determines would render participation in this study as unsafe for the participant","85 Years",{"count":215,"type":22},[196],"The overall goal of this proposed study is to evaluate the efficacy of a small-group, stroke-specific, self-management program delivered via telehealth to improve self-efficacy, activity performance, and quality of life in individuals with sub-acute stroke.",[473],"Stroke",[473,475,476,477,478],"Self-Management","Telehealth","Activities of daily living","Community engagement","2026-04-22",{"date":292,"type":35},{"date":482,"type":35},"2024-12-16",{"date":484,"type":22},"2029-12-15",{"name":41,"class":42},{"id":487,"slug":488,"hasResults":12,"nctId":489,"briefTitle":490,"officialTitle":490,"acronym":4,"eligibilityCriteria":491,"healthyVolunteers":16,"sex":50,"minAge":18,"maxAge":174,"enrollmentInfo":492,"targetDuration":4,"studyType":23,"phases":494,"briefSummary":495,"conditions":496,"keywords":498,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":43},"100630572","impact-of-sleep-restriction-on-blood-pressure-reactivity-100630572","NCT07489417","Impact of Sleep Restriction on Blood Pressure Reactivity","Inclusion Criteria:\n\n* Healthy adult men and women\n* 18-45 years of age\n* BMI \\\u003C 25 kg\u002Fm² (normal weight group) or ≥ 30 kg\u002Fm² (obesity group)\n* Non-pregnant, non-breastfeeding, and non-nicotine users\n* Self-reported history of normal sleep duration (7-9 hours\u002Fnight) and bedtime prior to midnight\n* Premenopausal\n\nExclusion Criteria:\n\n* No acute or chronic conditions\n* Taking no medications known to affect sleep, autonomic, metabolic, or cardiovascular function\n* Self-reported history of irregular sleep\n* Self-reported history of hepatic, renal, pulmonary, cardiovascular, or neurological disease, stroke or neurovascular disease, bleeding\u002Fclotting disorders, sleep apnea or other sleep disorders, diabetes, history of alcoholism or substance abuse, major cardiovascular event or surgical procedure within the past three months, or hypertension",{"count":493,"type":22},45,[196],"The purpose of the research study is to examine the effects of shortened sleep on blood pressure.",[343,497],"Blood Pressure",[343,499],"Blood pressure","2026-03-17",{"date":502,"type":35},"2026-03-24",{"date":504,"type":35},"2026-03-04",{"date":506,"type":22},"2027-08",{"name":41,"class":42},{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":4,"eligibilityCriteria":514,"healthyVolunteers":12,"sex":50,"minAge":18,"maxAge":4,"enrollmentInfo":515,"targetDuration":4,"studyType":23,"phases":516,"briefSummary":517,"conditions":518,"keywords":537,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":43},"100629707","effects-of-whole-body-electrical-muscle-stimulation-exercise-on-adults-with-neuromuscular-disease-100629707","NCT07478172","Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease","Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults withNeuromuscular Disease","Inclusion Criteria:\n\n* Age 18 or older\n* Diagnosed with one or more of the following neuromuscular conditions: Amyotrophic lateral sclerosis, primary lateral sclerosis, progressive muscle atrophy, spinal muscular atrophy, postpolio syndrome, inclusion body myositis, pompedisease, fascioscapulohumeral muscular dystrophy, charcot marie tooth disease, chronic inflammatory demyelinating polyneuropathy, hereditary spastic paraplegia, myasthenia gravis, lambert-eaton myasthenic syndrome, postural orthostatic tachycardia syndrome, mitochondrial myopathy, nemaline myopathy, centronuclear myopathy, lumbar radiculopathy, non-specific low back pain.\n* Ability to stand for approximately 15 minutes continuously with or without an assistive device (i.e. the length of time to stand to take a shower, complete meal preparation, wait in line at the bank, etc.)\n* At least some anti-gravity strength in major muscle groups as assessed by manual muscle testing (i.e. 2+\u002F5 strength or better)\n* Medical clearance to participate in an exercise program\n* Ability to provide informed consent\n* Ability to conform to the requirements of the study (i.e. attendance at assessment and intervention visits, maintain current level of non-study physical activity for the duration of the study, no intention to relocate mid-study)\n\nExclusion Criteria:\n\n* Diagnosed with one of the following neuromuscular conditions: Becker's muscular dystrophy, Duchenne muscular dystrophy, limb-girdle muscular dystrophy, myotonic dystrophy type 1 or 2, Freidrich's ataxia, any other NMD with known or suspected cardiac involvement or muscle fiber structural integrity defects.\n* Concurrent participation in another interventional research study\n* Unable to tolerate 15 minutes of continuous standing with or without an assistive device\n* Presence of a pacemaker, metal implants, or other implanted medical devices that could impact participant safety during WB-EMS intervention\n* Presence of cochlear implant, cortical stimulator, deep brain stimulator, ventriculoperitoneal shunt, recent skull defect, seizure in the past 12 months while taking anti-epilepsy medication, or previous serious adverse event with TMS, which could impact participant safety during TMS testing\n* Presence of unstable acute or chronic disease (i.e. renal failure, rheumatologic disease, cardia arrhythmia, neoplasm, uncontrolled hypertension)\n* Known pregnancy at time of screening; verbal screening will occur throughout the study.\n* Presence of a terminal disease (i.e. receiving hospice services)\n* Current or previous use of any drugs known to influence muscle mass or performance within 6 months; these may include but are not limited to anabolic steroids, IGF01, growth hormone, replacement androgen therapy, anti-androgen therapy\n* Presence of an additional neurologic conditions affecting somatosensory or motor function\u002Fcontrol (i.e. Parkinson's disease, Multiple Sclerosis, h\u002Fo stroke, TBI, SCI, ataxia, apraxia, hemiplegia, etc.)\n* Musculoskeletal condition or surgery in the past year that would confound results of exercise interventions (i.e. TKA, THA, RTC repair, spinal fusion)\n* Other medical conditions, signs, or symptoms that would interfere with study conductor interpretation of results as determined by an investigator",{"count":78,"type":22},[196],"This single-arm pilot study evaluates the effects of whole-body electrical muscle stimulation (WB-EMS) exercise on neuromuscular and physical function in adults with neuromuscular disease (NMD). Due to motor unit impairments, NMD patients often cannot tolerate traditional exercise. WB-EMS bypasses voluntary activation limits by directly stimulating muscle contractions. Up to 50 adults with conditions like ALS, SMA, and MG will undergo 20-minute supervised WB-EMS sessions (1-2 times weekly for 4-8 weeks) using the Katalyst system. Outcomes include neural excitability (TMS), motor unit behavior (EMG, NCS), functional tests (walk, balance, strength), and patient-reported fatigue, pain, and quality of life. Strict safety monitoring and exclusion criteria are in place. This study will provide preliminary data on WB-EMS as a potential exercise modality for NMD.",[519,520,521,522,523,524,525,526,527,528,529,530,531,532,533,534,535,536],"Neuromuscular Diseases (NMD)","Amyotrophic Lateral Sclerosis","Myasthenia Gravis","Lambert-eaton Myasthenic Syndrome","Primary Lateral Sclerosis","Spinal Muscular Atrophy","Charcot Marie Tooth Disease (CMT)","Fascioscapulohumeral Muscular Dystrophy","Inclusion Body Myositis","Mitochondrial Myopathy","Nemaline Myopathy","Centronuclear Myopathy","Postpolio Syndrome","Pompe Disease (Late-onset)","Chronic Inflammatory Demyelinating Polyneuropathy","Hereditary Spastic Paraplegia","Postural Orthostatic Tachycardia Syndrome (POTS)","Progressive Muscular Atrophy",[538,539,540,541],"Neuromuscular Disease","Electrical Stimulation","Whole Body stimulation","Exercise intervention","2026-03-12",{"date":500,"type":35},{"date":545,"type":35},"2026-03-10",{"date":547,"type":22},"2031-01-07",{"name":41,"class":42},{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":4,"eligibilityCriteria":555,"healthyVolunteers":16,"sex":50,"minAge":18,"maxAge":335,"enrollmentInfo":556,"targetDuration":4,"studyType":23,"phases":558,"briefSummary":559,"conditions":560,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":43},"100609875","impact-of-phenylalanine-elevations-on-brain-and-cognition-in-adult-pku-carriers-100609875","NCT07220265","Impact of Phenylalanine Elevations on Brain and Cognition in Adult PKU Carriers","The Impact of Phenylalanine Elevations on Metabolic, Cognitive, and Neural Functioning in Adults Heterozygous for Phenylketonuria (PKU)","Inclusion Criteria:\n\n* Age 18-60 years\n* For the PKU carrier group: Individuals who are the parent of an individual with PKU or who are otherwise have confirmed PKU carrier status (e.g., a sibling of someone with PKU who has had genetic testing done)\n* For the non-carrier group: Individuals who do not have PKU or a family history of PKU\n\nExclusion Criteria:\n\n* Obesity as defined by a body mass index (BMI) over 30\\*\n* Taking oral contraceptives on the day of testing session\\*\n* Positive cotinine urine test showing nicotine use\n* History of major neurologic condition (e.g., multiple sclerosis, severe closed head injury, Parkinson's disease)) unrelated to PKU and known to adversely impact brain health and function\n* Contraindications for safe MRI participation such as (a) pregnancy or plans to become pregnant during period of study enrollment; or (b) metallic objects inside the body (e.g., surgical staples left in the body following surgery, middle ear prosthesis, metal foreign objects lodged inside the eye, heart pacemakers).",{"count":557,"type":22},36,[196],"The goal of this clinical trial is to advance our understanding of the cognitive and neurophysiologic sequelae associated with suboptimal phenylalanine (Phe) metabolism in heterozygous carriers of phenylketonuria (PKU). The main questions it aims to answer are:\n\n* Do PKU carriers experience prolonged elevations in brain Phe levels following oral ingestion of dietary Phe?\n* Do PKU carriers experience disruptions in cognitive functioning following oral ingestion of dietary Phe?\n* Do PKU carriers experience atypical brain activity following oral ingestion of dietary Phe? Researchers will compare PKU carriers and non-carriers following oral ingestion of dietary Phe and a placebo.\n\nParticipants will:\n\n* Consume Phe or a placebo at two separate visits to our facility\n* At each visit, they will complete a series of MRIs and cognitive tests throughout the day",[561,136],"Carrier of Phenylketonuria","2026-03-09",{"date":564,"type":35},"2026-03-11",{"date":566,"type":35},"2025-12-19",{"date":568,"type":22},"2026-12-31",{"name":41,"class":42},{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":4,"eligibilityCriteria":576,"healthyVolunteers":12,"sex":50,"minAge":577,"maxAge":578,"enrollmentInfo":579,"targetDuration":4,"studyType":23,"phases":581,"briefSummary":582,"conditions":583,"keywords":586,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":589,"lastUpdatePostDateStruct":590,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":43},"100609535","pars-healing-on-mri-100609535","NCT07215845","Pars Healing on MRI","Pars Healing on oZTEo MRI","Inclusion Criteria:\n\n* 12-30 years old\n* Symptoms of back pain at the time of enrollment\n* Clinical imaging demonstrating pars stress interarticularis injury or pars interarticularis defect\n\nExclusion Criteria:\n\n* Prior lumbar surgery\n* Any condition for which an MRI procedure is contraindicated (e.g., metallic material in the body such as pacemakers, metallic clips, etc.)\n* Pregnancy\n* Likelihood of claustrophobia\n* Any patient-related factors that compromised quality on the initial diagnostic scan (patient motion, ascites fluid, difficulty with positioning during the scan)","12 Years","30 Years",{"count":580,"type":22},40,[196],"The goal of this clinical trial is to learn more about the natural healing process of pars stress injuries in adolescents and young adults by documenting bony bridging across stress fractures using Magnetic Resonance Imaging (MRI). It is hypothesized that many of these injuries can and will heal with appropriate rest and rehabilitation. Long-term, it is hoped that follow-up MRI exams can help guide clinical management by visualizing the healing and allowing individuals to return to play after bony bridging has occurred.\n\nParticipants will be asked to undergo serial MRI scans over the course of a 12-month period and answer a brief questionnaire at each visit.",[584,585],"Pars Interarticularis Stress Fracture","Pars Interarticularis Stress Injury",[587,584,585,588],"MRI","Pars","2026-03-06",{"date":562,"type":35},{"date":592,"type":35},"2025-12-12",{"date":594,"type":22},"2028-12-31",{"name":41,"class":42},{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":4,"eligibilityCriteria":602,"healthyVolunteers":12,"sex":17,"minAge":603,"maxAge":192,"enrollmentInfo":604,"targetDuration":4,"studyType":23,"phases":605,"briefSummary":606,"conditions":607,"keywords":609,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":614,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":43},"100557971","cognitive-rehabilitation-following-breast-cancer-treatment-100557971","NCT06545045","Cognitive Rehabilitation Following Breast Cancer Treatment","Pilot Testing of Metacognitive Strategy Training to Address Cancer-related Cognitive Impairment in Breast Cancer","Inclusion Criteria:\n\n* self-reported CRCI (Global Rating of Cognition dysfunction as \"Moderately\" \"Strongly \"or \"Extremely\" AND a Cognitive Failures Questionnaire1 (CFQ) score \\>30)\n* completed treatment for active cancer diagnosis (invasive ductal or lobular BrCA Stages I, II, or III) at least 6 months but not greater than 3 years prior to participation\n* able to read, write, and speak English fluently\n* able to provide valid informed consent\n* have a life expectancy of greater than 6 months at time of enrollment\n* on stable doses (i.e., no changes in past 90 days) of medications that are known to impact cognitive function (i.e., anti-depressants)\n\nExclusion Criteria:\n\n* prior cancer diagnoses of other sites with evidence of active disease within the past year\n* active diagnoses of any acute or chronic brain-related neurological conditions that can alter normal brain anatomy or function (e.g., Parkinson's disease, dementia, cerebral infarcts) dementia symptoms as indicated by a score of \\\u003C23 on the Montreal Cognitive Assessment (MoCA)\n* severe depressive symptoms (Personal Health Questionnaire-9 (PHQ-9) score of ≥21)\n* history of severe traumatic brain injury, prolonged loss of consciousness (e.g., coma)\n* conditions contraindicated for MRI (e.g., electrical implants, pumps, claustrophobia)\n* blue-yellow colorblindness\n* pregnancy\n\nThe screening methods identified in parentheses next to appropriate inclusion\u002Fexclusion criteria will be used to verify appropriate selection of study participants.","20 Years",{"count":78,"type":22},[196],"The goal of this proposed project is to evaluate the feasibility and preliminary effect of metacognitive strategy training to improve activity performance, cognition, and quality of life in breast cancer survivors with cancer-related cognitive impairment (CRCI). The other goal of this proposed project is to examine the effects of CO-OP on resting (rsFC)- and task-state functional connectivity as compared to an inactive control group.",[608],"Breast Cancer Female",[415,610,611,612,477],"Breast Cancer","Cognition","Metacognition","2026-02-17",{"date":615,"type":35},"2026-02-19",{"date":617,"type":35},"2024-10-31",{"date":619,"type":22},"2026-06-30",{"name":41,"class":42},""]